Laura Biganzoli

Dr. Laura Biganzoli

"Sandro Pitigliani" Medical Oncology Department - Hospital of Prato S. Stefano
orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Annals of Oncology
Verified
Journal Article
Closed access
FCF. Cardoso
F. Cardoso
SPS. Paluch-Shimon
S. Paluch-Shimon
ESE. Senkus
E. Senkus
GCGiuseppe Curigliano
Giuseppe Curigliano
MAM.S. Aapro
M.S. Aapro
EWE.P. Winer
E.P. Winer

19 July 2018 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
FCF. Cardoso
F. Cardoso
ESElżbieta Senkus
Elżbieta Senkus
ACA. Costa
A. Costa
EPE. Papadopoulos
E. Papadopoulos
MAM. Aapro
M. Aapro
EWE.P. Winer
E.P. Winer
Advanced Breast Cancer (ABC) comprises both locally advanced breast cancer (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, MBC remains virtually an incurable disease with a median overall survival (OS) of ∼3 years and a 5-year survival of only ∼25% [2, 3]. The MBC Decade Report [2] shows that progress has been slow in terms of improved outcomes, quality of life (QoL), awareness and information regarding ABC. More recently, some studies seem to indicate an improvement in OS, mostly due to advances in human epidermal growth factor receptor 2 (HER2)-positive ABC [4–6]. The better survival is seen in an environment with access to the best available care and particularly in de novo ABC, while recurrent ABC seems to become harder to manage [7, 8].

1 April 2012 in The Lancet Oncology
Verified
Journal Article
Closed access
Laura BiganzoliLaura Biganzoli
Laura Biganzoli
HWHans Wildiers
Hans Wildiers
COCatherine Oakman
Catherine Oakman
LMLorenza Marotti
Lorenza Marotti
SLSibylle Loibl
Sibylle Loibl
RARiccardo Audisio
Riccardo Audisio

1 March 2019 in The Lancet Oncology
Verified
Journal Article
Closed access
SLSherene Loi
Sherene Loi
AGAnita Giobbie-Hurder
Anita Giobbie-Hurder
AGAndrea Gombos
Andrea Gombos
TBThomas Bachelot
Thomas Bachelot
RHRina Hui
Rina Hui
PSPatrick Schneier
Patrick Schneier

5 December 2016 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
FCF. Cardoso
F. Cardoso
ACA. Costa
A. Costa
ESElżbieta Senkus
Elżbieta Senkus
MAM. Aapro
M. Aapro
FAF. André
F. André
EWE. Winer
E. Winer
Advanced Breast Cancer (ABC) comprises both locally advanced (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, MBC remains an incurable disease with a median overall survival of ∼2–3 years and a 5-year survival of only ∼25% [2–4]. Some more recent series seem to indicate an improvement in median overall survival [5, 6].

18 September 2014 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
FCF. Cardoso
F. Cardoso
ACA. Costa
A. Costa
LNL. Norton
L. Norton
ESElżbieta Senkus
Elżbieta Senkus
MAM. Aapro
M. Aapro
EWE. Winer
E. Winer
Advanced breast cancer (ABC) is a treatable but still generally incurable disease. The goals of care are to optimize both length and quality of life. Due to continuous research, several advances have been made, particularly for the human epidermal growth factor receptor 2 (HER-2)-positive and for luminal-like subtypes. Notwithstanding these advances, median overall survival of patients with ABC is still only 2–3 years, although the range is wide [1–5], and survival may be longer for patients treated in specialized institutions [6]. Implementation of current knowledge is highly variable among countries and within each country.